CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies

Biomarker Research

Volumn 2, Issue 1, 2014, Pages

  Testa, Ugo ^a   Pelosi, Elvira ^a   Frankel, Arthur ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD123 ANTIGEN; DIPHTHERIA TOXIN; INTERLEUKIN 3 RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLASTIC NK CELL LYMPHOMA; CELL PROLIFERATION; GENE MUTATION; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; LEUKEMIA REMISSION; LYMPHATIC LEUKEMIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPLENIC MARGINAL ZONE LYMPHOMA;

EID: 84904460162     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-2-4     Document Type: Review

References (74)

1. Hercus TR, Dhagak U, Kan W, Broughton S, Nero T, Perugini M, Sandow JJ, D'Andrea RJ, Ekert PG, Hughes T, Parker MW, Lopez AF. Signaling by the βc family of cytokines. Cytokine Growth Fact Rev 2013, 24(3):189-201.
2. Hercus TR, Broughton S, Ekert P, Ramshaw H, Perugini M, Grinbalsdeston M, Woodcock JM, Thomas D, Pitson S, Hughes T, D'Andrea RJ, Parker MW, Lopez AF. The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors 2012, 30(2):63-75. 10.3109/08977194.2011.649919, 22257375.
3. Braughton S, Dhagat U, Hercus TR, Nero T, Grinbaldeston M, Bonder C, Lopez AF, Parker MW. The GM-CSF/IL-3/GM-CSF cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev 2012, 250(1):277-302. 10.1111/j.1600-065X.2012.01164.x, 23046136.
4. Lopez AF, Hercus TR, Ekert P, Littler D, Guthdridge M, Thomas D, Ramshaw HS, Stomski F, Perugini M, D'Andrea R, Grimbaldeston M, Parker MW. Molecular basis of cytokine receptor activation. IUBMB Life 2010, 62(7):509-518. 10.1002/iub.350, 20540154.
5. Ihle JN. Interleukin-3 and hematopoiesis. Chem Immunol 1992, 51:65-106.
6. Lantz CS, Boesiger J, Song CH, Mach CN, Kobayashi T, Mulligan RC, Nawa Y, Dranoff G, Galli SJ. Role of uinterleukin-3 in mast-cell and basophilk development and in immunity to parasites. Nature 1998, 392(6671):90-93. 10.1038/32190, 9510253.
7. Rothenberg ME, Oxen WF, Siberstein DS, Woods J, Soberman RJ, Austen KF, Stevens RL. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest 1988, 81(6):1986-1992. 10.1172/JCI113547, 442652, 3133397.
8. Brizzi MF, Garbarino G, Rossi PR, Pagliardi GL, Arduino C, Avanzi GC, Pegoraro L. Interleukin 3 stimulates proliferation and triggers endothelial leukocyte adhesion molecule 1 gene activation of human endothelial cells. J Clin Invest 1993, 91(6):2887-2892. 10.1172/JCI116534, 443359, 7685775.
9. Woodcock JM, Bagely CJ, Zacharakis B, Lopez AF. A single tyrosine residue in the membrane-proximal domain of the GM-CSF, IL-3 and IL-5 receptor common beta chain is necessary and sufficient for high affinity binding and signalling by all three ligands. J Biol Chem 1996, 271(42):25999-26006. 10.1074/jbc.271.42.25999, 8824238.
10. Barry SC, Korpelainen E, Sun Q, Stomski FC, Moretti PA, Wakao H, D'Andrea RJ, Vadas MA, Lopez AF, Goodal GJ. Roles of the N and C terminal domains of the interleukin-3 receptor alpha chain in receptor function. Blood 1997, 89(3):842-852.
11. Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, Mann DA, Woltring DM, Walker I, Ollis DL, Young IG. Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, IL-5 receptors reveals a novel dimer configuration. Cell 2011, 104(2):291-300.
12. Woodcock JM, McClure BJ, Stomski FC, Eliott MJ, Bagley CJ, Lopez AF. The human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor exists as a preformed complex that can be activated by GM-CSF, interleukin-3 or interleukin-5. Blood 1997, 90(8):3005-3017.
13. Sato N, Caux C, Kitamura T, Watanabe Y, Arai K, Banchereau J, Miyajima A, et al. Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells. Blood 1993, 82(3):752-761.
14. Wognum AR, de Jong MO, Wagemaker G. Differential expression of receptors for hemopoietic growth factors on subsets of CD34+ hemopoietic cells. Leuk Lymphoma 1996, 24(1-2):11-25.
15. Huang S, Chen Z, Yu JF, Young D, Bashey A, Ho AD, Law P. Correlation between IL-3 receptor expression and growth potential of human CD34+ hematopoietic cells from different tissues. Stem Cells 1999, 17(5):265-272. 10.1002/stem.170265, 10527461.
16. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A 2002, 99(18):11872-11877. 10.1073/pnas.172384399, 129361, 12193648.
17. Testa U, Fossati C, Samoggia P, Macsiulli R, Mariani G, Hassan J, Sposi NM, Guerriero R, Rosato V, Gabbianelli M, Pelosi E, Valtieri M, Peschle C. Expression of growth factor receptors in unilineage differentiation culture of purified hematopoietic progenitors. Blood 1996, 88(9):3391-3406.
18. Militi S, Riccioni R, Parolini I, Sposi NM, Samoggia P, Pelosi E, Testa U, Peschle C. Expression of interleukin 3 and granulocyte-macrophage colony stimulating receptor common chain beta C, beta IT in normal hematopoiesis: lineage specificity and proliferation-independent induction. Brit J Haematol 2000, 111(2):441-451.
19. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, Luongo JL, Danet-Desnoyers GA, Bonnet D. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005, 106(13):4086-4092. 10.1182/blood-2005-03-1072, 1895250, 16131573.
20. Jin L, Lee EM, Ramshaw HS, Busfiled SJ, Peoppl AG, Wilkinson L, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB. Monoclonal-antibody mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemia stem cells. Cell Stem Cell 2009, 5(1):31-42. 10.1016/j.stem.2009.04.018, 19570512.
21. Olweus J, Bitmansour A, Warnike R, Thompson P, Caraballido J, Picker LJ, Lund-Johansen F. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci U S A 1997, 94(23):12551-12556. 10.1073/pnas.94.23.12551, 25034, 9356487.
22. MacDonald KP, Mauster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN. Characterization of human blood dendritic cell subsets. Blood 2002, 100(13):4512-4520. 10.1182/blood-2001-11-0097, 12393628.
23. Chaperot L, Bendriss N, Manches O, Gressin R, Magnadie M, Trimoreau Orfeuvre H, Corront B, Feuillard J, Sotto JJ, Bensa JC, Brière F, Plumas J, Jacob MC. Identification of a leukemic counterpart of the plasmocytoid dendritic cells. Blood 2001, 97(10):3210-3217. 10.1182/blood.V97.10.3210, 11342451.
24. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Tromoreau F, Selles E, Salaun V, Garand R, Lepelley P, Maynadié M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC, . GOELAMS and GEIL study Extended diagnostic criteria for plasmocytoid dendritic cell leukemia. Brit J Haematol 2009, 145(5):624-636. GOELAMS and GEIL study.
25. Narita M, Kuroha T, Watanabe N, Hashimoto S, Tuschiyama J, Tockiki N, Saitoh A, Satoh N, Furukawa T, Toba K, Fuse I, Aizawa Y, Takahashi M. Plasmocytoid dendritic cell leukemia with potent antigen-presenting ability. Acta Haematol 2008, 120(2):91-99. 10.1159/000165510, 18948686.
26. Buelens C, Bartholome EJ, Amraoui Z, Boutriaux M, Salmon I, Thielemans K, Willems F, Goldman M. Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood 2002, 99(3):993-998. 10.1182/blood.V99.3.993, 11807004.
27. Demoulin S, Roncarati P, Delvenn P, Hubert P. Production of large numbers of plasmocytoid dendritic cells with functional activities from CD34+ hematopoietic progenitor cells: use of interleukin-3. Exp Hematol 2012, 40(2):268-278.
28. Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P, . European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties Stem cell tramsplantation can provide durable disease control in blastic plasmocytoid dendritic cell neoplasm: a retrospective study from the European Group and blood marrow transplantation. Blood 2013, 121(3):440-446. 10.1182/blood-2012-08-448613, 23203822, European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties.
29. Pagano L, Valentini GC, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, Di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, Pileri S, Leone G, Amadori S, Facchetti F, . GIMEMA-ALWP (Gruppo Italiano Malattie Ematologiche dell'Adulto, Acute Leukemia Working Party) Blast plasmocytoid dendritic cell neoplasm with leukemic presentation: an italian multicenter study. Haematologica 2013, 98(2):239-246. 10.3324/haematol.2012.072645, 3561431, 23065521, GIMEMA-ALWP (Gruppo Italiano Malattie Ematologiche dell'Adulto, Acute Leukemia Working Party).
30. Frankel AE, Woo JH, Mauldin JP, Carraway HE, Frankfurt O, Forman SJ, et al. An update on the robust clinical activity of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood 2013, 122(21):abstract nr 64672.
31. Munoz L, Nomdedeu JF, Lopez O, Cornier MJ, Bellido M, Aventin A, Brunet S, Sierra J. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 2001, 86(12):1261-1269.
32. Del Giudice I, Matutes E, Morilla R, Morilla A, Owusu-Ankomah K, Rafiq F, A'Hern R, Delgado J, Bazerbashi MB, Catovsky D. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004, 89(3):303-308.
33. Shao K, Calvo KR, Grouborg M, Temhore PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 2013, 37(4):401-409. 10.1016/j.leukres.2012.11.021, 23347903.
34. Venkataram G, Aguhar C, Kretiman R, Yuan C, Stetler-Stevenson M. Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia. Am J Clin Pathol 2011, 136(4):625-630. 10.1309/AJCPKUM9J4IXCWEU, 21917686.
35. Testa U, Riccioni R, Coccia E, Stellacci E, Samoggia P, Latagliata R, Latagliata R, Mariani G, Rossini A, Battistini A, Lo-Coco F, Peschle C. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced bast proliferation, increased cellularity and poor prognosis. Blood 2002, 100(8):2980-2988. 10.1182/blood-2002-03-0852, 12351411.
36. Djokic M, Bjorklund E, Blennow E, Mazur J, Soderhall S, Powirt A. Overexpression of CD123 correlates with hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica 2009, 94(7):1016-1019. 10.3324/haematol.2008.000299, 2704314, 19454491.
37. Hassanein N, Alcancia F, Perkinson K, Buckley P, Lagoo A. Distinct expression patterns of CD123 and CD 34 on normal bone marrow B-cell precursors (" hematogenes" ) and B lymphoblastic leukemia blasts. Am J Clin Pathol 2009, 132(4):573-580. 10.1309/AJCPO4DS0GTLSOEI, 19762535.
38. Constan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, Downing JR, Campana D. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011, 117(23):6267-6276. 10.1182/blood-2010-12-324004, 3122946, 21487112.
39. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL. The interleukin-3 receptor alpha is a unique marker for human acute myelogenous leukemis stem cells. Leukemia 2000, 14(10):1777-1784. 10.1038/sj.leu.2401903, 11021753.
40. Testa U, Riccioni R, Diverio D, Rossini A, Lo-Coco F, Peschle C. Interleukin 3 receptor in acute leukemia. Leukemia 2004, 18(2):219-226. 10.1038/sj.leu.2403224, 14671644.
41. Riccioni R, Diverio D, Riti V, Buffolino S, Mariani G, Boe A, Cedrone M, Ottone T, Foà R, Testa U. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukemias with mutated FMS-related tyrosine kinase 3 receptor. Brit J Haematol 2009, 144(3):376-387.
42. Riccioni R, Pelosi E, Riti V, Castelli G, Lo-Coco F, Testa U. Immunophenotypic features of acute myeloid leukemia patients exhibiting high Flt3 expression not associated with mutations. Brit J Haematol 2011, 153:33-42.
43. Rollins-Raval M, Pillai R, Mitsuhashi-Warita T, Metha R, Boyadzisn M, Djokic M, Roth C. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl Immunohistochem Mol Morphol 2013, 21(3):212-217.
44. Gonen M, Sun Z, Figueroa MA, Patel JP, Abdel-Waheb O, Racevskis J, Ketterling RP, Fernandez H, Rowe JM, Tallman MS, Melnick A, Levine RL, Paietta E. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood 2012, 120(11):2297-2306. 10.1182/blood-2012-02-414425, 3447784, 22855599.
45. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT. Nuclear factor-kappa B is constitutively activated in primitive acute human acute myelogenous leukemia cells. Blood 2011, 98(8):2301-2307.
46. Hwang K, Park CJ, Jang S, Chi HS, Kim DY, Lee JH, Im HJ, Seo JJ. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann Hematol 2012, 91(10):1541-1546. 10.1007/s00277-012-1501-7, 22669506.
47. Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N, Ifrah N, Dreyfus F, Manenti S, Demur C, Delabesse E, Lacombe C, Mayeux P, Bouscary D, Recher C, Bardet V. High levels of CD34+CD38low/-/CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia. Haematologica 2011, 96:1792-1798. 10.3324/haematol.2011.047894, 3232261, 21933861.
48. Du W, Li XE, Sipple J, Pang Q. Overexpression of IL-3Ralpha on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML. Blood 2011, 117(16):4243-4252. 10.1182/blood-2010-09-309179, 3087476, 21330473.
49. Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukemia. Nat Rev Clin Oncol 2013, 10(8):460-471. 10.1038/nrclinonc.2013.100, 23799371.
50. Larsen HO, Roug AS, Just J, Brown GD, Hokland P. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. Cytometry 2012, 82(1):3-8.
51. Roug AS, Larsen HO, Nedeiby L, Just T, Brown G, Nyvold C, Ommen H, Hokland P. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukemia. Brit J Haematol 2014, 164(1):212-222.
52. Nederby L, Hokland P, Brown G, Hansen M, Nyvold CG, Roug AS. Unraveling the leukemic nature of hMICL and CD123 expressing cells in acute myeloid leukemia. Blood 2013, 122:Abstract 2626.
53. Han L, Jorgensen JL, Wang SA, Huang X, Gonzalez GN, Brooks C, Rowinsky E, Levis M, Zhou J, Ciurea SO, Alatrash G, Cortes JE, Kantarjian HM, Andreef M, Ravandi F, Konopleva M. Leukemia stem cell marker CD123 (IL-3R alpha) predicts minimal residual disease and relapse, providing a valid target for SL-101 in acute myeloid leukemia with FLT3-ITD mutations. Blood 2013, 122:Abstract 359.
54. Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, Kucera GL, Alexander RL, Beran M, Tagge EP, Kreitman RJ, Hogge DE. Diphteria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000, 14(4):576-585. 10.1038/sj.leu.2401743, 10764142.
55. Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Toxicology and pharmacokinetics of DT388IL3, a fusion protein consisting of a truncated diphteria toxin (DT388) linked to human interleukin 3 (IL3) in cymolgous monkeys. Leuk Lymphoma 2004, 45(9):1647-1656.
56. Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Safety evaluation of DT388IL3, a diphteria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother 2005, 54(5):799-806.
57. Testa U, Riccioni R, Biffoni M, Diverio D, Lo-Coco F, Foà R, Peschle C, Frankel A. Diphteria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood 2005, 106(7):2527-2529. 10.1182/blood-2005-02-0540, 1895267, 15928038.
58. Yalcintepe L, Frankel AE, Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphteria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 2006, 108(10):3530-3537. 10.1182/blood-2006-04-013813, 16882709.
59. Hogge DE, Yalcintepe L, Wong SH, Gerhard B, Frankel AE. Variant diphteria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 2006, 12(4):1284-1291. 10.1158/1078-0432.CCR-05-2070, 16489085.
60. Sun Q, Woodcock JM, Rapoport A, Stomski FC, Korpelainen EI, Bagley CJ, Goodall GJ, Smith WB, Gamble JR, Vadas MA, Lopez AF. Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific receptor antagonist. Blood 1996, 87(1):83-92.
61. Leyton JV, Hu M, Gao C, Turner PV, Dick JE, Minden M, Reilly RM. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population. J Nucl Med 2011, 52(9):1465-1473. 10.2967/jnumed.111.087668, 21816968.
62. Busfield S, Brodo M, Wong M, Ramshaw H, Lee EM, Martin K, Ghosh S, Braley H, Tomasetig V, Panousis C, Vairo G, Roberts AW, He S, Sprigg N, Thomas D, DeWitte M, Lock R, Lopez AF, Nash A. CSL362: a monoclonal antibody to human interleukin 3 receptor (CD123), optimised for NK cell-mediated cytotoxicity of AML stem cells. Blood 2012, 120:Abstract 3598.
63. Herzog E, Busfield S, Biondo M, Vairo G, DeWitte M, Pragst I, Dickneite G, Nash A, Zollner S. Pharmacodynamic activity and preclinical safety of CSL363, a novel humanised, affinity-matured monoclonal antibody against haman interleukin 3 receptor. Blood 2012, 120:Abstract 1524.
64. Lee EM, Yee D, Busfield S, Vairo G, Lock R. A neutralizing antibody (CSL362) against the interleukin-3 receptor alpha-chain augments the efficacy of a cytabarine/daunorubicin induction-type therapy in preclinical xenograft models of acute myelogenous leukemia. Blood 2012, 120:Abstract 3599.
65. Nievergall E, Ramshaw HS, Yong A, Biondo M, Busfield SJ, Vairo G, Lopez AF, Hughes TP, White DL, Hiwase DK. Monoclonal antibody targeting IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood 2014, in press.
66. Kuo SR, Wong L, Liu JS. Engineering of a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Sel 2012, 25(7):561-569.
67. Hussaini M, Ritchey J, Retting MP, Eissenberg L, Uy G, Chichili G, Moore PA, Johnson S, Collins R, Bonvini E, DiPersion JF. Targeting CD123 in leukemic stem cells using dual affinity re-targeting molecules (DARTs). Blood 2013, 122:Abstract 360.
68. Stein C, Kellner C, Kugler M, Reiff N, Mentz K, Schwenkert M, Stockmeyer B, Mackensen A, Fey GH. Novel conjugates of single chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukemia cells. Brit J Haematol 2010, 148(6):879-889.
69. Kugler M, Stein C, Kellner C, Mentz K, Saul D, Schwenvert M, Schubert I, Singer H, Oduncu F, Stockmeyer B, Mackensen A, Fey GH. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukemia cells by dual targeting. Brit J Haematol 2010, 150(5):574-586.
70. Tettamanti S, Marin V, Pizzitola I, Magnani C, Giordano Attianese G, Cribioli E, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, Bonnet D, Biagi E. Targeting of acute myeloid leukemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Brit J Haematol 2013, 161(3):389-401.
71. Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ. T cells expressing CD123-specific cytolytic effector functions and anti-tumor effects against human acute myeloid leukemia. Blood 2013, in press.
72. Gill S, Tasian S, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desoyers G, Scholler J, Grupp SA, June CH, Kalos M. Anti-CD123 chimeric antigen receptor T cells (CART-123) provide a novel myeloablative conditioning regimen that eradicates human acute myeloid leukemia in preclinical models. Blood 2013, 122:Abstract 143.
73. Frankel AE, Konopleva M, Hogge D, Rizzieri D, Brooks C, Cirrito T, et al. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. J Clin Oncol 2013, 31(suppl):abstract nr 7029.
74. Roberts AW, He S, Ritchie D, Hertzberg MS, Kerridge I, et al. A phase I study of anti-CD123 monoclonal antibody (CD123) CSL360 targeting leukemia stem cells (LSC) in AML. J Clin Oncol 2010, 28:abstract nr e13012.